Medinice (WAR:ICE) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:ICE Medinice SA WAR:ICE
25 GF Score
Price zł73.40
GF Value zł0.99
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Medinice Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

WAR:ICE
25GF Score
Medinice SA WAR:ICE
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Medinice (WAR:ICE) Overvalued in 2026?

Based on GuruFocus' analysis, Medinice stock appears to be overvalued. The current stock price of zł73.40 is trading 7314.1% above its estimated GF Value™ of zł0.99. GuruFocus considers Medinice to be Significantly Overvalued.

Key valuation signals for WAR:ICE:

  • Dividends Received:
  • GF Value™: zł0.99 vs. price of zł73.40 (7314.1% above fair value)
  • GF Score™: 25/100 with 1 warning sign

No single metric tells the full story. See the WAR:ICE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medinice Business Description

Other Exchanges 77E:Germany
Address Hankiewicza Street 2, Warszawa, POL, 02-103
Medinice SA is a Polish company operating in the MedTech industry. The company is engaged in creating, developing and commercializing solutions in the field of medicine, in particular, cardiology and cardio surgery. Its portfolio includes close around 12 projects including CathAIO, an electrode with universal diagnostic, electrophysiological, haemodinamic and biohemic functions and can be used for RF ablation; cryoapplicator, for minimally invasive cardiosurgical cryoablation; Med-iConsole allows to reduce the need to use multiple computer devices during electrophysiological treatment; Minimax and Pacepress.
25GF Score

Get the complete analysis for WAR:ICE

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł73.40
Price
zł0.99
GF Value